(MENAFN) GlaxoSmithKline, Britain's largest drug maker, will pay USD105 million to settle claims from California, New York and more than 40 other states that it illegally promoted asthma and antidepressant drugs, according to Arab News.
Glaxo will be prohibited under the accord from providing incentive payments to salespeople that encourage off-label drug uses, and from using paid doctors to promote its products.
The agreement covers the asthma drug Advair and two antidepressant drugs, Paxil and Wellbutrin.
California's portion of the settlement, the largest of any state, is USD7.1 million.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.